Celcuity
Celcuity Studying Nerlynx Activity in HER2-Negative Breast Cancer With Hyperactive HER2 Signaling
The company will use its CELsignia test to identify metastatic breast cancer patients eligible to receive the pan-HER inhibitor with chemo within a Phase II trial.
Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement
The company is studying gedatolisib with palbociclib and endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer.
Celcuity Using CELSignia Test to Select Breast Cancer Patients for Phase II Trial of Tabrecta, Nerlynx
The company's test will identify patients who have dysregulated HER2 and c-MET signaling despite having normal HER2 expression in tumors.
Pfizer, Celcuity Partner on Phase II Breast Cancer Trial of Vizimpro, Xalkori
Celcuity will use its CELsignia Multi-Pathway Activity Test to identify patients with hyperactive HER2 and c-MET signaling pathways.